The USFDA has recently approved the first antibody-drug conjugate, mirvetuximab soravtansine , for treating folate receptor alpha positive, platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer. The drug has been approved for patients who have undergone a maximum of three systemic treatments previously. Study details The efficacy of the trial was evaluated in a single-arm clinical trial containing 106 patients with folate receptor-positive, platinum-resistant ovarian, peritoneal, or fallopian tube cancer who had undergone one to three prior systemic therapy regimens, at least one of which contained bevacizumab.
Overall response rate = 31.7% The median duration of response = 6.9 months The drug is administered as an IV infusion of 6 mg/kg every three weeks. Treatment-associated adverse events include: Vision impairment Increased levels of alanine aminotransferase…
